Wimasis starts the official sales phase of the quantitative tube formation assay “WimTube” which had been developed since middle of November 2009 and is now ready for the commercial use.

ibidi signed agreement on distribution of Wimasis WimTube within their own product portfolio.

STMWIVT accepted the project application „AUTRACK“ and gives an allowance for the development of an innovative cell tracking algorithm in label-free cell-based assays.

The main R&D project of Wimasis S.L., SEACI-M3A, will be supported by INNPACTO and INNCORPORA programs.

The entire Wimasis team met at the Wimasis S.L. office in Córdoba, Spain, to hold
the 1st Annual Meeting of Wimasis.

Wimasis will provide webinars regularly about its products and the assays which are
still in the development phase.

Wimasis launches the beta version of its tube formation analysis tool, which is available as free and automated solution on the myWim platform.

ibidi GmbH starts officially marketing WimScratch within their own product portfolio providing it by special conditions.

Wimasis presents its products at the cell-based assay conference in the Hilton London Olympia, London, UK, from 20th to 22nd of September.

Wimasis S.L. signed cooperation agreement with CIB-CSIC and FPS.

Wimasis GmbH creates its first subsidiary, Wimasis S.L., in Córdoba, Spain.

Wimasis presents the product release of its quantitative wound healing assay “WimScratch” at analytica 2010 in Munich.

Wimasis offers new ways to analyze cell images through its Software-as-a-Service (SaaS) solution. By interacting with Wimasis.com, researchers are able to quantify images of their cell-based assay research fast and easily while achieving cost efficiency.

From now on, the development of a chemotaxis assay enlarges the product portfolio of Wimasis.

Wimasis GmbH announces a cooperation with ibidi GmbH in the development and sale of a Quantitative Wound Healing Assay.

Wimasis is introducing myWim, a pay-per-image web-based quantitative image analysis (QIA) platform to enable objectivity and cost efficiency for between cell-based research stakeholders. Wimasis believes its QIA offering via myWim, a Software-as-a-service (SaaS) web platform, is compelling enough to convince market participants.

Wimasis initiates a development project for quantitative tube formation image analysis.

Wimasis initiates its development activities in quantitative wound healing analysis.

The image analysis service provider Wimasis GmbH, located in Munich, is officially set up. It differs by offering a web-based platform, that is handling the entire process of the analysis.